Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 5/20 | 0.48 |
| ▸ | CNR1 | P21554 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19617998 | 1.00 | HPGD (0.56) | HPGDTAAR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL15478179 | 0.94 | HPGD (0.50) | HPGDTAAR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10030734 | 0.91 | THRB (0.50) | HPGDTAAR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL10030730 | 0.89 | HPGD (0.54) | HPGDTAAR1CNR2HDAC1HDAC2 | |
| SCHEMBL10030728 | 0.86 | EPHX2 (0.50) | HPGDHDAC1HDAC2EPHX2 | |
| SCHEMBL838460 | 0.85 | MAPT (0.50) | SMN1; SMN2CNR2CNR1MAPT | |
| SCHEMBL10030727 | 0.84 | MEN1 (0.57) | HPGDMEN1KMT2AEPHX2 | |
| SCHEMBL15917151 | 0.84 | HPGD (0.41) | HPGDTAAR1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13182760 | 0.84 | MAPT (0.47) | SMN1; SMN2CNR2CNR1MAPT | |
| SCHEMBL3230032 | 0.83 | DGKA (0.66) | HDAC1HDAC2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11143958-B2 | Method for applying curable gellant composition for digital embossing and other raised print applications | XEROX CORPORATION (US) | 2021-10-12 | — | — | US | disclosed |
| US-20190310550-A1 | Method For Applying Curable Gellant Composition For Digital Embossing And Other Raised Print Applications | XEROX CORPORATION | 2019-10-10 | — | — | US | disclosed |
| EP-3312246-B1 | INK COMPOSITION COMPRISING PHASE CHANGE TRANSFER ADDITIVE FOR DIGITAL OFFSET PRINTING | XEROX CORP (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10308827-B2 | Ink jet ink compositions for digital manufacturing of transparent objects | XEROX CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3312246-A1 | INK COMPOSITION COMPRISING PHASE CHANGE TRANSFER ADDITIVE FOR DIGITAL OFFSET PRINTING | Xerox Corporation (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20180105712-A1 | Ink Composition Comprising Phase Change Transfer Additive For Digital Offset Printing | XEROX CORPORATION | 2018-04-19 | — | — | US | disclosed |
| US-20180105712-A1 | Ink Composition Comprising Phase Change Transfer Additive For Digital Offset Printing | XEROX CORPORATION | 2018-04-19 | — | — | US | disclosed |
| US-20180072899-A1 | PHASE-CHANGE DIGITAL ADVANCED LITHOGRAPHIC IMAGING INKS WITH AMIDE GELLANT TRANSFER ADDITIVES | XEROX CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20180072899-A1 | PHASE-CHANGE DIGITAL ADVANCED LITHOGRAPHIC IMAGING INKS WITH AMIDE GELLANT TRANSFER ADDITIVES | XEROX CORPORATION | 2018-03-15 | — | — | US | disclosed |
| US-20170275486-A1 | Curable Gellant Ink Composition | XEROX CORPORATION | 2017-09-28 | — | — | US | disclosed |
| US-8084637-B2 | Amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084637-B2 | Amide gellant compounds with aromatic end groups | XEROX CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110262643-A1 | INK COMPOSITIONS AND METHODS | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262711-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262643-A1 | INK COMPOSITIONS AND METHODS | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263769-A1 | Phase Change Inks Containing Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263769-A1 | Phase Change Inks Containing Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110262711-A1 | CURABLE COMPOSITIONS FOR THREE-DIMENSIONAL PRINTING | XEROX CORPORATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263890-A1 | Amide Gellant Compounds With Aromatic End Groups | NAT1, AGPAT2, CCNT1 | HPGD 3248/4885TAAR1 380/4885SMN1; SMN2 4399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.